Purdue’s Mung Chiang outlines a bold vision to transform university research funding through deeper industry, philanthropic, ...

SiteOne Therapeutics is developing a non-opioid therapy that targets sodium ion channels in the human body to treat pain and ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...

Eli Lilly and Company has received marketing authorisation from the Australian Therapeutic Goods Administration (TGA) for ...

Global pharmaceutical giant Eli Lilly & Co. is seeking tax incentives for a potential 236-acre biomanufacturing plant in ...

Novo Nordisk announced it will work with the biotech Septerna to develop oral GLP-1 obesity drugs in a deal worth up to $2.2 billion, including $200 million upfront. GSK is paying $1.2 billion upfront ...

The test can aid doctors in determining whether a patient's memory problems are due to Alzheimer's or a number of other ...

Eli Lilly has unveiled plans to expand its long-standing partnership with Purdue University, with the drugmaker investing up ...

DIANT Pharma Signs Collaborative Accord to Strengthen U.S. Pharmaceutical Manufacturing DIANT is proud to stand alongside forward-thinking leaders who recognize the urgent need to modernize and secure ...

Eli Lilly and Company and Purdue University announced today a significant expansion of their long-standing alliance, with Lilly's planned investment of up to $250 million in the collaboration over the ...

Eli Lilly is pumping iron in the GLP-1 prescription ring, gaining muscle with a 52.4% market share and a beefy $1,100 target.

Eli Lilly and Co. and Purdue University announced Friday that Lilly will invest $250 million in a collaboration between the ...